Olmesartan Medoxomilo + Hidroclorotiazida Farmoz (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomilo + Hidroclorotiazida Farmoz, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension, often in combination with a diuretic, and is indicated for adults. GNH USA supplies Olmesartan Medoxomilo + Hidroclorotiazida Farmoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartan Medoxomilo + Hidroclorotiazida Farmoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan medoxil combined with hydrochlorothiazide is used to manage high blood pressure by targeting the renin‑angiotensin‑aldosterone system.

- Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Heart failure prevention: assists in controlling blood pressure to lessen workload on the heart. - Chronic kidney disease: helps slow progression by managing hypertension in patients with renal impairment.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Dizziness - Headache - Fatigue - Increased urination - Electrolyte imbalance (low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia - Angio‑edema - Liver function abnormalities - Blood cell disorders (e.g., agranulocytosis).

Patients should be evaluated for contraindications and monitored throughout treatment.

- Renal impairment: adjust dose and monitor kidney function. - Hepatic disease: use with caution; monitor liver enzymes. - Electrolyte disturbances: check serum potassium and sodium regularly. - Pregnancy: contraindicated in the second and third trimesters; avoid use. - Elderly patients: start at lower dose and monitor for orthostatic hypotension. - Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Olmesartan medoxil + Hydrochlorothide may interact with several drug classes.

Major Interactions (Avoid): - Potassium‑rich supplements or potassium‑sparing diuretics: risk of hyperkalemia. - Aliskiren (in diabetic patients): increased risk of renal dysfunction. - NSAIDs (high‑dose): may blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Lithium: may increase serum lithium levels. - Antifungal azoles (e.g., ketoconazole): can raise olmesartan concentrations. - Beta‑blockers: additive blood‑pressure lowering effect. - ACE inhibitors: combined use may increase risk of renal impairment and hyperkalemia.